This newsletter presents you the following presentations:
1. Adding bevacizumab to endocrine therapy as first-line therapy for women with advanced breast cancer
does not impact survival
2. The Breast Cancer Index (BCI) is a significant prognostic factor for the prediction of late disease
recurrence
3. Hypofractionated radiotherapy is safe and effective for early breast cancer treatment at 10-years of
follow-up